Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.48
-0.14 (-2.49%)
At close: Aug 29, 2025, 4:00 PM
5.48
0.00 (0.00%)
After-hours: Aug 29, 2025, 4:10 PM EDT
Solid Biosciences Employees
Solid Biosciences had 100 employees as of December 31, 2024. The number of employees increased by 12 or 13.64% compared to the previous year.
Employees
100
Change (1Y)
12
Growth (1Y)
13.64%
Revenue / Employee
n/a
Profits / Employee
-$1,540,840
Market Cap
426.72M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 12 | 13.64% |
| Dec 31, 2023 | 88 | 1 | 1.15% |
| Dec 31, 2022 | 87 | -17 | -16.35% |
| Dec 31, 2021 | 104 | 34 | 48.57% |
| Dec 31, 2020 | 70 | -51 | -42.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLDB News
- 1 day ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 weeks ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - GlobeNewsWire
- 7 weeks ago - Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade) - Seeking Alpha
- 7 weeks ago - SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm - PRNewsWire
- 7 weeks ago - Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - GlobeNewsWire
- 3 months ago - Solid Biosciences to Participate at the Jefferies Global Healthcare Conference - GlobeNewsWire